Kisspeptin sits at the very top of the reproductive hormone cascade. It is the signal that tells GnRH neurons to fire, which tells the pituitary to release LH, which tells the testes to make testosterone. If your secondary hypogonadism is caused by insufficient hypothalamic drive, a kisspeptin analog should be the perfect fix — upstream of everything, correcting the root cause. Pharmaceutical companies bet hundreds of millions on this logic. They lost.
This is the story of why kisspeptin therapy keeps failing in clinical trials, what it teaches us about how the HPG axis actually works, and why there may still be hope.
The Discovery That Changed Reproductive Endocrinology
In 2003, two independent research groups — one led by Seminara at Harvard, the other by de Roux in Paris — published back-to-back papers in the New England Journal of Medicine and Proceedings of the National Academy of Sciences. Both groups had found families with idiopathic hypogonadotropic hypogonadism (IHH) who carried mutations in a single gene: KISS1R, the receptor for kisspeptin.
The implication was immediate: kisspeptin signaling is essential for reproductive function. Without it, puberty doesn't happen. GnRH neurons don't fire. The entire HPG axis sits dormant.
Over the next decade, research confirmed kisspeptin's role as the master switch. Kisspeptin neurons in the arcuate nucleus (called KNDy neurons because they co-express kisspeptin, neurokinin B, and dynorphin) act as the pulse generator for GnRH release. They fire in coordinated bursts, and each burst triggers a pulse of GnRH, which triggers a pulse of LH, which drives testosterone production.
Kisspeptin sits at the apex of the HPG axis. KNDy neurons fire in pulses, driving the entire downstream cascade. Testosterone feeds back to suppress kisspeptin release — closing the loop.
The keyword here is pulses. KNDy neurons don't secrete kisspeptin continuously. They fire in coordinated bursts, roughly every 60–90 minutes. This pulsatility isn't a quirk of the system — it is the system. And this is where things went wrong.
The Acute Promise
Early human studies were electric. A single bolus injection of kisspeptin-54 (the natural 54-amino-acid form) in healthy men produced a rapid, robust rise in LH and testosterone. The dose-response was clean and reproducible.
Dhillo et al. (2005) showed that intravenous kisspeptin-54 in healthy men stimulated LH release within minutes. Subsequent studies confirmed that even kisspeptin-10 (a truncated but potent fragment) could drive dose-dependent LH surges and measurable testosterone increases.
The most compelling acute data came from continuous infusion studies. Jayasena et al. showed that a 22.5-hour infusion of kisspeptin-10 at 4 μg/kg/h increased testosterone from 16.6 to 24.0 nmol/L (p<0.001) and increased LH pulse frequency. Over a single day, kisspeptin was doing exactly what theory predicted.
Pharmaceutical interest followed. Takeda developed TAK-448, a synthetic kisspeptin analog with a half-life of 108 minutes (compared to kisspeptin-54's 28 minutes). It was potent, with an IC50 of 460 pM and EC50 of 632 pM at the KISS1R receptor. A drug you could actually develop.
The Paradox Emerges
Then they tried to use it chronically, and the paradox appeared.
In Phase 1 studies, TAK-448 administered as a single bolus or short infusion stimulated testosterone 1.3–2x over 48 hours. Promising. But when they switched to a 14-day continuous subcutaneous infusion, the picture inverted completely:
- Testosterone rose initially
- By 60 hours, T had dropped below baseline
- By day 8, testosterone had reached castration levels
Schematic based on TAK-448 Phase 1 data. A single bolus drives T up. Continuous infusion initially stimulates, then suppresses T to castration levels by ~day 8.
Continuous kisspeptin exposure was doing the opposite of what it was supposed to do. Instead of maintaining testosterone, it was chemically castrating patients.
If this sounds familiar, it should. It's exactly what happens with GnRH agonists like leuprolide (Lupron). Give a GnRH agonist acutely and you get a surge of LH and testosterone. Give it continuously and you suppress the axis — which is why GnRH agonists are used to treat prostate cancer by eliminating testosterone.
Kisspeptin is one step upstream of GnRH, and it exhibits the same paradox: acute stimulation, chronic suppression. The mechanism is receptor desensitization — continuous agonist exposure causes KISS1R downregulation and internalization. The GnRH neurons stop responding.
Takeda's Gamble: The TAK-448 Phase 2 Trial
Despite the Phase 1 warning signs, Takeda pushed into Phase 2 (NCT02381288). The trial enrolled overweight men with type 2 diabetes who also had hypogonadotropic hypogonadism — a population where secondary hypogonadism is common and undertreated.
The design was open-label and adaptive. Takeda tried multiple dosing regimens, attempting to find a schedule that could sustain testosterone in the normal range. The thinking was that perhaps intermittent dosing, pulse-like administration, or optimized dose levels could thread the needle between stimulation and desensitization.
They found that TAK-448 acutely stimulated testosterone in a clear dose-dependent fashion. But no regimen maintained testosterone in the normal range. The primary endpoints were not met. The trial was terminated in December 2016.
Takeda offloaded the kisspeptin program to Roivant Sciences, which spun it into Myovant Sciences. Myovant pivoted the molecule (now called MVT-602) away from male hypogonadism entirely, focusing instead on using kisspeptin as an acute trigger for oocyte maturation in IVF — a setting where a single bolus is all you need.
The irony is stark. The molecule works beautifully as a one-time signal. It fails as a chronic therapy. The business followed the biology.
Why Pulsatility Is Not Optional
The failure of continuous kisspeptin is not a failure of the molecule. It's a vindication of how the reproductive axis is designed.
The HPG axis is a pulsatile system. KNDy neurons fire in bursts. GnRH is released in pulses. LH is secreted in pulses. Even testosterone has diurnal rhythmicity. Every level of the cascade depends on intermittent signaling, and every receptor in the chain is designed to reset between signals.
When you flood any of these receptors with continuous agonist — whether it's GnRH or kisspeptin — they desensitize. The receptor internalizes. Signal transduction stops. The system shuts down.
Animal data drives the point home. Thompson et al. showed that continuous subcutaneous kisspeptin-54 infusion (50 nmol/day for 13 days) in rats caused:
- Decreased LH, FSH, and testosterone
- Reduced testis weight
- Decreased sperm count and motility
- Seminiferous tubule degeneration and germ cell apoptosis
Continuous kisspeptin didn't just fail to stimulate — it actively damaged the reproductive system. The tachyphylaxis data from MVT-602 human studies confirmed a threshold: at steady-state concentrations above ~228 pg/mL (186 pmol/L), the axis reliably shuts down.
This is not a design flaw. It's a feature. The receptor desensitization mechanism exists to protect against aberrant continuous stimulation. The reproductive axis is not a light switch. It's a rhythm.
The Pulsatile Hope
If the problem is continuous exposure, the solution is pulsatile delivery. And there is evidence this could work.
Kisspeptin-10 given as intermittent bolus injections consistently stimulates LH without the desensitization seen with continuous infusion. A 1 μg/kg bolus produces maximal LH stimulation. The key finding from infusion studies is that lower-dose kisspeptin-10 (1.5 μg/kg/h over 22.5 hours) increased LH pulse frequency without clear tachyphylaxis — suggesting that dose and delivery pattern can prevent receptor downregulation.
Two clinical trials are now testing this concept directly:
Both trials are still recruiting, with no published results yet. The approach mimics the natural firing pattern of KNDy neurons — delivering kisspeptin in pulses rather than continuously, allowing receptor recovery between doses.
The concept is directly analogous to pulsatile GnRH pump therapy, which has been used successfully for decades to treat IHH. Continuous GnRH suppresses the axis; pulsatile GnRH restores it. If the same principle holds one level upstream, pulsatile kisspeptin could restore the axis from an even more physiological starting point.
Who Would Kisspeptin Actually Help?
Here's a critical nuance from the research that often gets overlooked. Not all secondary hypogonadism responds to kisspeptin the same way.
Studies in patients with abiding congenital IHH — those whose GnRH neurons never properly developed or migrated — show poor responses to kisspeptin. This makes sense: kisspeptin works by activating GnRH neurons. If those neurons are absent or permanently dysfunctional, no amount of kisspeptin will help.
But patients with reversed IHH (those who initially had IHH but spontaneously recovered, then relapsed) show robust kisspeptin responses. Their GnRH neurons exist and are functional — they just need the right input signal.
This distinction maps directly onto the broader secondary hypogonadism population:
- Functional secondary hypogonadism (obesity, metabolic syndrome, opioid-induced, stress, sleep deprivation) → GnRH neurons are intact but underactivated → kisspeptin should work
- Organic hypothalamic/pituitary lesions (tumors, infiltrative disease, congenital GnRH deficiency) → GnRH neurons may be damaged or absent → kisspeptin likely won't help
This means the ideal candidate for kisspeptin therapy is the most common type of secondary hypogonadism: the man whose axis is intact but underperforming. The overweight patient. The man on chronic opioids. The stressed, sleep-deprived patient with borderline testosterone. Their GnRH neurons are there, waiting. They just aren't getting enough kisspeptin signal.
Where We Stand
Kisspeptin therapy for male hypogonadism is in a strange place. The biology is compelling. The acute pharmacology is proven. The mechanism of action is as upstream and physiological as you can get. But the delivery problem — how to chronically administer a peptide that demands pulsatile exposure — remains unsolved.
The two ongoing pulsatile pump trials are the most important studies in this space. If pulsatile kisspeptin can sustain testosterone without tachyphylaxis over 2 weeks, it would be proof-of-concept for a fundamentally new class of hypogonadism therapy — one that works with the axis rather than replacing or bypassing parts of it.
But even with positive results, practical challenges loom. A subcutaneous pump every 1–4 hours is manageable for research but burdensome for chronic daily treatment. The path from pump to practical therapy would require either:
- Long-acting pulsatile formulations — depot injections engineered to release kisspeptin in pulses (challenging but not impossible with modern polymer-based delivery systems)
- Oral kisspeptin analogs — small-molecule KISS1R agonists that could be taken in timed doses
- Kisspeptin neuron-activating drugs — compounds that enhance endogenous kisspeptin signaling rather than replacing it (neurokinin B receptor agonists or dynorphin antagonists, targeting the other components of the KNDy system)
The last option is particularly intriguing. Instead of delivering exogenous kisspeptin, you could amplify the body's own kisspeptin pulse generator. Neurokinin B stimulates kisspeptin release from KNDy neurons. A selective NK3 receptor agonist could theoretically boost endogenous kisspeptin pulsatility without the tachyphylaxis risk of exogenous kisspeptin.
The Lesson
The kisspeptin story teaches something fundamental about the HPG axis: the signal matters less than the pattern. Kisspeptin is the right molecule at the right target. But delivered in the wrong pattern, it becomes its own opposite — a suppressor rather than a stimulator.
This principle extends beyond kisspeptin. It explains why GnRH agonists suppress testosterone. It informs how we think about all hormonal therapies. And it underscores why the body's endogenous pulsatile signaling is so sophisticated — and so difficult to replicate pharmacologically.
For men with secondary hypogonadism, kisspeptin remains the most physiological target imaginable. Whether we can harness it practically is the open question. The answer may come from the two pump trials currently recruiting. I'll be watching.
Key References: Seminara et al., NEJM 2003 (KISS1R mutations in IHH); de Roux et al., PNAS 2003; Dhillo et al., JCEM 2005 (kisspeptin-54 in healthy men); Jayasena et al., JCEM (KP-10 infusion, testosterone increase); MacLean et al. (TAK-448 Phase 1, continuous infusion tachyphylaxis); NCT02381288 (TAK-448 Phase 2, terminated 2016); Thompson et al. (continuous kisspeptin in rats — testicular degeneration); Chan et al. (kisspeptin response in abiding vs reversed IHH); NCT04648969, NCT05896293 (ongoing pulsatile kisspeptin trials).